Stocks · News reference
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 566.67 percent decrease over losses of $(0.12) per
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
Filed: 2026-09-08 AccNo: 0001759425-26-000047 Size: 143 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.